Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

The question I hear most often from patients considering a GLP-1 medication is not “will it work?” Most of them have already read enough to believe it will work. The question I hear most is “will I lose muscle?” It is a real concern, and the answer is nuanced in a way that a quick internet search does not capture well. GLP-1 muscle loss is real, but the degree to which it happens depends enormously on what a patient does around the medication, specifically how much protein they eat and whether they are doing resistance training.

What Lean Mass Loss on GLP-1 Therapy Actually Looks Like

A portion of any significant weight loss comes from lean tissue, not just fat. This is true of weight loss by any method: dietary restriction, bariatric surgery, or GLP-1 therapy. In my clinical experience, GLP-1 medications do not independently accelerate muscle loss beyond what losing weight by any means would produce. A meaningful share of weight lost comes from lean tissue when patients do not engage in structured resistance training, with the majority coming from fat.

The problem is not the drug. The problem is that when appetite suppression reduces food intake significantly, protein often falls along with total calories, and lean tissue pays the price. That is the pattern I see repeatedly in patients who lose weight quickly without a deliberate protein and training plan in place.

The patients who do this program right lose fat. The patients who simply inject without adjusting protein intake lose fat and muscle together. There is a meaningful clinical difference in body composition outcomes between those two groups, and the separating variable is not the medication. It is what happens around it.

For patients considering adding sermorelin to their GLP-1 protocol to further support lean mass through the GH/IGF-1 axis, see The Combination We Prescribe When Patients Want to Lose Weight Without Losing Muscle.

The Leucine Threshold and Why Protein Distribution Matters

Understanding why protein distribution across meals matters requires a brief explanation of how muscle protein synthesis actually works at the cellular level. Muscle protein synthesis is regulated in large part through the mTOR pathway, a cellular signaling system that acts as a nutrient sensor and growth regulator. Among the amino acids that activate mTOR, leucine is the most potent trigger. Research has established a leucine threshold: approximately 2.5 to 3 grams of leucine per meal is required to maximally stimulate muscle protein synthesis via mTOR. Below that threshold, the anabolic response is blunted.

The clinical target I set for patients on GLP-1 therapy includes not just a total daily protein number but a per-meal distribution framework: 1.2 to 1.6 grams of protein per kilogram of body weight per day, distributed across at least three meals, with each meal containing a minimum of 30 to 40 grams of high-quality protein.

What I consistently see in practice is that many patients cannot reliably hit these targets once they are well into therapy, because appetite is substantially blunted. One large protein meal at dinner does not produce the same anabolic effect as three meals each crossing the leucine threshold throughout the day. The mTOR signal fires and fades. It needs to be re-triggered at each meal to sustain the rate of muscle protein synthesis that counteracts the catabolic forces of a caloric deficit.

Resistance Training: The Mechanical Signal That Walking Cannot Replace

The second pillar of the protocol is resistance training, and this is where I encounter the most pushback from patients. Patients who are losing weight are often tired, often dealing with nausea at some point in titration, and often inclined to believe that walking or light cardio is sufficient. The biology says otherwise.

Resistance training preserves muscle through a specific biological mechanism: mechanical tension applied to a muscle triggers the activation of satellite cells, the resident stem cells of skeletal muscle tissue. Satellite cells proliferate and fuse with existing muscle fibers, contributing to myofibrillar protein synthesis and structural repair. This mechanical tension signal is distinct from metabolic or hormonal stimuli. It requires that the muscle be loaded near its capacity to generate the cellular response that signals the body to maintain and rebuild fiber density.

Walking does not provide this stimulus at a meaningful level for most patients. Aerobic exercise has well-documented cardiovascular and metabolic benefits, and I want all patients incorporating regular low-intensity movement. But aerobic exercise and resistance training do different things to skeletal muscle biology. During a caloric deficit, when the body’s default tendency is to catabolize protein from muscle to meet energy needs, resistance training sends a countervailing signal: this tissue is being used, do not sacrifice it. Without that signal, the proportion of lean mass lost during weight reduction is higher than it needs to be.

The protocol I recommend is a minimum of two to three resistance training sessions per week, each focusing on compound movements that recruit large muscle groups: squats, deadlifts, presses, rows, and lunges. Patients who do not have gym access or equipment can achieve adequate mechanical stimulus with bodyweight exercises performed to near muscular failure.

Understanding Hair Loss: The Same Upstream Cause

Patients often come to me alarmed about hair shedding during GLP-1 therapy. The clinical term for this phenomenon is telogen effluvium, and understanding the mechanism explains why it shares an upstream cause with lean mass loss.

The hair follicle cycles through growth phases: anagen is the active growth phase, and telogen is the resting phase from which hair sheds. Under normal conditions, approximately 10 to 15 percent of follicles are in the telogen phase at any time. When the body experiences significant physiological stress, including rapid caloric restriction or major nutritional deficits, a larger-than-normal fraction of follicles shift from anagen into telogen simultaneously. The timing of this shift typically lags the stressor by two to three months, which is why patients often notice hair shedding well after the period of most rapid weight loss began.

Patients who maintain adequate protein intake and avoid severe caloric restriction beyond what the medication naturally produces tend to experience less pronounced hair shedding and faster recovery. Both problems have the same upstream solution: protect protein intake and do not compound the medication’s caloric suppression with additional aggressive dieting.

The Full Protocol in Practice

The protocol I give patients starting a GLP-1 has three components. First, a protein target: 1.2 to 1.6 grams per kilogram of body weight per day, distributed across at least three meals, each crossing the leucine threshold with 30 to 40 grams of protein. Second, resistance training: two to three sessions per week, full body, compound movements performed with enough load to generate real mechanical tension. Third, restraint around additional caloric restriction: let the drug do what it does. Stacking an aggressive low-calorie diet on top of a medication that is already reducing intake significantly produces a deficit larger than needed, a protein shortfall more severe, and a lean mass cost higher than necessary.

Patients who follow this framework lose fat and maintain a substantially higher proportion of lean mass than patients who treat the medication as the only variable in the equation.

FAQ

Q: How much muscle loss is normal on a GLP-1 medication? A portion of the weight lost on GLP-1 therapy comes from lean tissue, with the majority coming from fat. This is comparable to what happens with weight loss through dietary restriction alone. The absolute amount of muscle lost depends significantly on protein intake and resistance training during the weight loss period.

Q: Is resistance training necessary, or is cardio sufficient? Cardiovascular exercise has meaningful health benefits, but it does not provide the mechanical stimulus that signals the body to preserve skeletal muscle during a caloric deficit. Resistance training two to three times per week is the clinically supported approach for muscle preservation. Both are beneficial; resistance training is the component that is non-substitutable for this specific goal.

Q: Why do patients experience hair shedding on GLP-1 medications? Hair shedding during GLP-1 therapy is most often telogen effluvium, a temporary shedding caused by the physiological stress of rapid caloric restriction and nutritional changes. It typically appears two to three months after the period of most rapid restriction and is not caused directly by the medication. Maintaining adequate protein intake reduces its severity and duration.

Q: What if appetite suppression makes hitting protein targets difficult? Protein shakes and protein-fortified foods are clinically appropriate tools for patients on GLP-1 therapy who struggle to reach targets through whole food alone. Prioritizing protein at every meal before moving to other macronutrients, and using a high-quality protein supplement for any meal where targets are difficult to meet, are practical strategies used regularly in our practice.

Q: Can muscle lost during the weight loss phase be recovered? Lean mass lost during the weight loss phase can be regained after reaching a stable weight, particularly with continued resistance training and adequate protein intake. Many patients experience meaningful improvements in body composition during a maintenance phase after active weight loss.

Q: How does Precision Telemed’s program support body composition? Precision Telemed providers offer ongoing async follow-up that includes guidance on nutrition and lifestyle practices during GLP-1 therapy. The goal of the program is not just weight reduction but overall metabolic and body composition improvement.

References

1. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. doi:10.1111/dom.15728
2. Ida S, Kaneko R, Imataka K, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024. PubMed: 39719170

To speak with one of our licensed providers about whether this is right for you, visit www.precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded NAD+ is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient came to our program after spending the better part of a year doing IV NAD+ infusions at a wellness clinic. She was paying $400 a session, going once a month when she could afford it, then nothing for two or three months when she couldn’t. She shared with our team that the sessions helped — noticeably. She had started to resent a therapy that was working because she couldn’t afford to keep it going.

When our program introduced subcutaneous NAD+ injections at $139.99 for the first month, then $149 a month, she was skeptical — she had been told IV was the only legitimate delivery route. Three months later she reported the same mental clarity and energy consistency she had gotten from the IV sessions, maintained daily rather than spiking and crashing around appointments she could only afford sporadically. That outcome shaped everything about how we built this program.

What NAD+ Is — From a Biochemistry Standpoint

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme present in every cell in the body. I want to explain the underlying science here as someone with a pharmaceutical background, not as clinical guidance.

NAD+ functions as an electron carrier in the mitochondrial electron transport chain — foundational to how cells convert nutrients into ATP. But it is also a consumed substrate for a class of enzymes that govern DNA repair, gene expression, and cellular stress response. Sirtuins (SIRT1 through SIRT7) require NAD+ as a cofactor for every catalytic cycle. SIRT1 regulates gene expression, inflammation, and stress resistance. SIRT3 governs mitochondrial biogenesis and antioxidant defenses within the organelle. PARPs consume NAD+ for DNA repair. CD38, a glycohydrolase involved in immune signaling, is another major consumer.

As we age, NAD+ levels fall. CD38 expression increases with aging and chronic inflammation, cleaving NAD+ continuously. PARPs run continuously in tissues under chronic oxidative stress. NAMPT — the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back to NAD+ — declines in activity. The consumption side accelerates while the synthesis side weakens.

The human clinical evidence is real. Trammell and colleagues documented a 2.7-fold increase in blood NAD+ following a single 1,000 mg dose of NR in healthy human subjects (Trammell et al., Nat Commun 2016, PMID 27721479). Yoshino and colleagues found NMN supplementation produced a 38 percent increase in intramuscular NAD+ and a 25 percent improvement in muscle insulin sensitivity in prediabetic women (Yoshino et al., Science 2021, PMID 34108263). I want to be transparent: a significant portion of mechanistic data comes from animal studies, and large-scale RCTs in humans are still ongoing. The mechanism is well understood; the long-term clinical evidence in humans continues to develop.

For a detailed comparison of subcutaneous versus IV delivery and why consistency matters more than peak concentration, see Why I Recommend Subcutaneous NAD+ Over IV Therapy.

Why the Delivery Model Matters — An Operational Observation

The IV model priced NAD+ therapy out of reach for most people who would benefit from sustained use. Four hundred to six hundred dollars per session, four to ten sessions for a loading protocol, at a clinic that requires hours out of the day. Most patients can’t sustain that, and the benefit tracks consistency — not the magnitude of any single dose.

Subcutaneous NAD+ at home produces lower peak concentration than IV, but more sustained availability across days. For the sirtuin-dependent pathways that require ongoing NAD+ to function, consistent replenishment is more valuable than periodic flooding. What I observed operationally across our patient population — not as a clinical conclusion, but as a pattern — is that patients on consistent subcutaneous protocols described outcomes that matched or exceeded what they’d gotten from sporadic IV sessions they could only afford a few times a year.

What Patients in Our Program Have Reported

The most consistent report from our NAD+ patient population is mental clarity — not a stimulant effect, but a more durable cognitive sharpness that feels less effortful. Sustained energy without relying on caffeine or stimulants is the second theme. Faster physical recovery from training is the third. These are patient-reported observations from our program, not clinical trial results. Individual experiences vary, and our clinical team evaluates each patient’s situation individually.

Who This Is and Is Not For

Our clinical team adds NAD+ to protocols for patients dealing with cognitive fatigue, active patients seeking improved recovery, and patients who have responded well to IV NAD+ but cannot sustain that cost model. It is not positioned as a treatment for disease. Anyone expecting a cure-all will be disappointed — our providers say so directly before moving forward.

For a clinical comparison of IV versus injection delivery, see NAD+ IV Therapy vs Injections: What the Difference Actually Means.

FAQ

What are the reported benefits of NAD+ injections?

Patients in our program most commonly report improved mental clarity, more sustained energy, and faster recovery from physical activity. These are consistent with the known role of NAD+ in mitochondrial energy production and sirtuin activation. Compounded NAD+ has not been reviewed by the FDA. Individual results vary.

How does subcutaneous NAD+ compare to IV NAD+?

IV produces a higher acute peak; subcutaneous produces slower absorption and more consistent availability across days. For ongoing sirtuin activity — which requires NAD+ as a stoichiometric substrate in every catalytic cycle — consistency of replenishment matters more than the magnitude of a single dose.

How much do NAD+ injections cost?

At Precision Telemed, subcutaneous NAD+ injections are $139.99 your first month, then $149 a month. IV NAD+ at wellness clinics typically costs $400–600 per session.

Is the research on NAD+ established?

The mechanism of action is well understood, and human clinical data is growing. Larger long-term RCTs are still ongoing. I am transparent with patients that this is not a therapy with 30 years of phase III trial evidence — and our clinical team has that conversation before anyone starts.

References

1. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PubMed
2. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient came in last year who had spent over $3,000 in a single quarter at an IV therapy clinic. The sessions were helping, she said. She felt sharper after each infusion, her energy held better for a week or so. Then her schedule changed and the costs caught up with her, and she stopped entirely. Six weeks later she felt exactly the way she had before she started.

That story reveals something important about NAD IV therapy and the biology of NAD+ restoration: the benefit tracks the consistency of replenishment, not the magnitude of any single dose. Understanding why requires a look at what NAD+ actually does at the cellular level and how its decline with age is driven by mechanisms that do not stop between infusion appointments.

What NAD+ Does and Why Restoration Matters

Nicotinamide adenine dinucleotide is a coenzyme found in every cell of the body. Its most fundamental role is as an electron carrier in metabolic redox reactions, shuttling reducing equivalents into the mitochondrial electron transport chain to drive ATP production. Without sufficient NAD+ to complete this cycling, mitochondrial energy output falls and cells become metabolically constrained.

But NAD+ is also a consumed substrate, not just a cycling carrier, in three critical regulatory pathways. Sirtuins, a family of seven deacetylase enzymes designated SIRT1 through SIRT7, require NAD+ for every catalytic cycle. SIRT1 deacetylates histones and transcription factors to regulate gene expression for inflammation, metabolic adaptation, and stress resistance. SIRT3 governs mitochondrial protein acetylation and protects against oxidative damage. PARPs, or poly-ADP-ribose polymerases, also consume NAD+ as a substrate for DNA repair. CD38, an enzyme with NAD+ glycohydrolase activity involved in immune signaling and calcium mobilization, is another major consumer. These are not minor diversions. They compete for the same NAD+ pool that the mitochondria need to sustain energy output.

The research supporting NAD+ restoration is mechanistically well understood. A landmark 2016 clinical trial led by Charles Brenner and Samuel Trammell, published in Nature Communications, was the first controlled human trial of nicotinamide riboside, an NAD+ precursor. The trial showed dose-dependent increases in blood NAD+ metabolites in healthy human subjects, with blood NAD+ rising as much as 2.7-fold after a single dose. No serious adverse events were observed across 36 days of observation. (PubMed)

Why NAD+ Declines With Age

NAD+ decline is driven by specific, identifiable mechanisms that accelerate over time. CD38 expression increases substantially with age and with chronic low-grade inflammation. As CD38 upregulates, it hydrolyzes NAD+ at an increasing rate, outpacing the body’s capacity to resynthesize it. This is compounded by PARP hyperactivation: decades of accumulated DNA damage mean more strand breaks and more PARP recruitment, each episode drawing down the NAD+ pool. At the same time, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway that recycles nicotinamide back into NAD+, declines in activity with age. The synthesis side weakens while the consumption side accelerates.

This mechanism matters for treatment decisions. If the problem were simply inadequate dietary intake, a single large dose once a month might suffice. But the problem is continuous enzymatic consumption that does not pause between appointments. The replenishment strategy needs to match the consumption pattern.

NAD IV Therapy: The Clinical Case and the Real Limitations

Intravenous NAD+ infusion delivers the coenzyme directly into circulation, achieving 100 percent bioavailability. A standard IV session uses 250 to 1,000 mg of NAD+ dissolved in saline, infused over two to four hours. The acute elevation in plasma NAD+ is rapid and substantial. For patients with severe depletion or who are going through addiction recovery protocols, that acute loading can be clinically appropriate and the high peak concentration may have specific therapeutic value.

But for the large majority of patients pursuing longevity, cognitive performance, metabolic health, and energy, the IV model creates practical barriers that undermine the very consistency the biology requires. Sessions cost $400 to $600 each. They require patients to take two to four hours out of their day, travel to a clinic, and sit attached to an IV line. Loading protocols often call for four to ten sessions over two to four weeks, a financial and logistical burden most patients cannot sustain. When patients stop, the benefit stops. NAD+ does not accumulate indefinitely. The CD38 enzymes keep working. The PARPs keep responding to DNA damage. The NAD+ that was transiently elevated is metabolized and cleared within hours to days, and the problem reasserts itself.

Why Subcutaneous Injection Achieves Comparable Systemic Results

Subcutaneous NAD+ injection delivers the compound into the tissue just below the skin, where it is absorbed steadily into systemic circulation. The bioavailability is lower than IV, approximately 70 to 80 percent, but the pharmacokinetics are actually favorable for the sustained cellular replenishment that sirtuin activation requires. Rather than a single large spike that peaks and then clears, subcutaneous injection delivers a more gradual, sustained elevation of plasma NAD+.

What the research supports is that for long-term outcomes, frequency of replenishment matters more than the route of a single large dose. Consistent, repeated elevation of NAD+ supports ongoing sirtuin activity, sustained mitochondrial function, and continuous DNA repair processes. The sirtuin enzymes require NAD+ as a stoichiometric substrate: every deacetylation reaction consumes one molecule of NAD+. Maintaining the baseline concentration that keeps SIRT1 and SIRT3 active requires steady replenishment, not periodic flooding.

Yoshino and colleagues, writing in Science in 2021, conducted a randomized, double-blind, placebo-controlled trial showing that NAD+ precursor supplementation increased intramuscular NAD+ levels by 38 percent and improved insulin sensitivity in skeletal muscle by 25 percent in prediabetic women, with SIRT1 activation confirmed by RNA sequencing. (PubMed) The delivery route in that trial was oral, not IV — reinforcing that tissue-level NAD+ elevation sufficient to activate sirtuins and improve metabolic function does not require intravenous delivery.

The Cost Reality and What Sustainability Actually Means

At Precision Telemed, the NAD+ program is $149.99 per month. A single IV session at a typical IV therapy clinic costs more than that. Two IV sessions per month, a conservative maintenance schedule by those clinics’ own protocols, costs $800 to $1,200 monthly.

Sustainable, in this context, is not a marketing word. It is a biological requirement. A therapy that raises NAD+ for three weeks and then disappears for a month does not confer lasting sirtuin activation. It does not produce durable mitochondrial improvement. The subcutaneous model at home, administered twice weekly during loading and then weekly for maintenance, is designed to match the biology. It keeps the NAD+ pool elevated continuously rather than cycling it sharply up and down.

Patients self-inject using a small insulin-gauge needle into the abdomen or outer thigh. The process takes under two minutes. There is no clinic visit, no IV line, and no $500 session fee.

How I Structure NAD+ Protocols at Precision Telemed

For most patients, I start with twice-weekly subcutaneous injections for the first four to six weeks as a loading phase, then taper to once weekly for maintenance. Patients report improvements in mental clarity, energy stability, sleep quality, and exercise recovery within the first two to four weeks of consistent use. The cognitive improvements, which are often what patients notice first — are consistent with SIRT1-mediated neurological effects and the mitochondrial energy requirements of neural tissue.

For patients managing metabolic conditions, age-related fatigue, or neurological symptoms, I may maintain the twice-weekly schedule longer before stepping down. The async model at Precision Telemed allows follow-up on lab values and symptom tracking without requiring in-person visits.

FAQ

Q: Is subcutaneous NAD+ as effective as IV therapy? For most patients pursuing sustained longevity and metabolic benefits, yes. IV therapy achieves a higher acute plasma NAD+ peak, but subcutaneous injection at regular intervals maintains the consistent baseline elevation that drives ongoing sirtuin activation and mitochondrial support. For sirtuin enzymes that require NAD+ as a stoichiometric substrate in every catalytic cycle, frequency of replenishment matters more than the magnitude of any single dose.

Q: How often should subcutaneous NAD+ be administered? Most protocols use twice weekly for the first four to six weeks as a loading phase, then once weekly for ongoing maintenance. The treating provider adjusts this based on symptoms and treatment goals.

Q: What does NAD+ actually do in the body? NAD+ functions as an electron carrier in mitochondrial redox reactions that produce ATP, and as a consumed substrate for sirtuin enzymes (SIRT1-7), PARP DNA repair enzymes, and CD38. Its decline with age reduces cellular energy output, impairs DNA repair, and suppresses sirtuin-mediated gene regulation.

Q: Why does NAD+ decline with age? CD38 expression increases with age and chronic inflammation, hydrolyzing NAD+ at an accelerating rate. PARP hyperactivation from accumulated DNA damage adds to consumption. Meanwhile, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, declines in activity. The result is a progressive imbalance between consumption and synthesis.

Q: Is self-injection at home safe? Yes, with proper instruction. Subcutaneous injection with an insulin-gauge needle into the abdomen or outer thigh is a well-established and low-risk technique. Precision Telemed patients receive complete injection education as part of their onboarding.

Q: How is Precision Telemed’s NAD+ program different from an IV clinic? Cost and consistency are the primary differences. At $149.99 per month, the program costs a fraction of a single IV session at most clinics. It is delivered to the patient’s door, administered at home in under two minutes, and managed asynchronously by a licensed provider. The weekly or twice-weekly schedule is designed to maintain NAD+ at biologically active levels continuously rather than episodically.

Q: Can NAD+ help with brain fog and cognitive performance? The research on SIRT1-mediated neurological regulation and the mitochondrial energy requirements of neural tissue is compelling, and many patients in our practice report meaningful improvements in clarity and sustained mental energy within the first few weeks of consistent use. This is positioned as a supportive intervention that addresses a documented biological mechanism — not a treatment for any diagnosed neurological condition.

References

1. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PubMed
2. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded testosterone cypionate is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient reached out to our program last year, about a week after his first consultation at a men’s clinic near him. He had gone in curious, left with a treatment plan, and then opened the invoice. He was looking at $450 a month, not including labs every three months. He made $62,000 a year. He said: “I can’t do this.” He was ready to just accept feeling the way he felt.

That call is why I address pricing in the first conversation, not the last. And it’s why I want to explain what TRT actually costs; what drives that cost, and where our $199 flat rate comes from — from someone with a pharmaceutical commercial background who understands what’s really going on in this market.

What’s In the Medication and Why the Price Isn’t What It Appears

Testosterone cypionate is the most widely prescribed form of injectable TRT. From a pharmaceutical manufacturing standpoint, it is not a complex or expensive compound to produce. Testosterone cypionate is esterified testosterone, a cypionate ester group attached at the C17 position, which gives it a half-life of approximately eight days and makes weekly or twice-weekly dosing practical. A 503A compounding pharmacy can produce a ten-week supply for a fraction of what traditional clinics charge.

The markup at most men’s health clinics has almost nothing to do with the cost of the drug. What patients are paying for is the building, the front desk, the PA, and a business model built around in-person volume. That’s the commercial reality, and it’s something my pharmaceutical trade background makes easy to see clearly.

The Pharmacology Behind Why Monitoring Is Part of the Cost

I want to explain what our clinical program includes and why, not as medical guidance, but as someone who understands the underlying pharmacology and built a program around it.

Testosterone operates within the hypothalamic-pituitary-testicular axis. When exogenous testosterone is introduced, the body’s feedback loop suppresses endogenous GnRH and LH, which reduces the testes’ own output. That is pharmacologically expected and something our clinical team discusses with every patient before they start. The Bhasin 2018 Endocrine Society guidelines establish diagnostic criteria, two separate morning total testosterone measurements below 300 ng/dL on different days. (Bhasin et al., J Clin Endocrinol Metab 2018, PMID 29562364).

Testosterone also has erythropoietic effects — it stimulates EPO production, which drives increased red blood cell production and raises hematocrit over time. That has cardiovascular implications at elevated levels. Our clinical team monitors hematocrit, total and free testosterone, and estradiol on a standard schedule. The lab work is not overhead I’m passing through to generate revenue. It’s the clinical obligation that comes with the therapy, and it’s why the program cost needs to include physician oversight, not just medication.

Testosterone also aromatizes to estradiol via the CYP19A1 enzyme. Our program includes anastrozole, an aromatase inhibitor, as a standard component rather than an add-on, because managing that ratio is part of doing this properly.

For a clinical explanation of side effects and what to expect, see Side Effects of Testosterone Injections: What to Expect.

What the $199 Flat Rate Includes

Our foundational TRT program is $199 a month. That covers testosterone cypionate compounded at our 503A pharmacy and shipped, anastrozole, and physician oversight — a licensed provider reviews each patient’s case, adjusts the protocol, and remains available through our telehealth platform. Baseline lab review is included when patients come in with existing labs.

I built the program this way because medication and medical oversight should be a single unit, not separated into individual line items to inflate the total. The clinics charging $500 a month are not necessarily doing better medicine. The services charging $50 with no real oversight are not doing medicine at all. We sit between those two points — pricing that is honest, oversight that is real.

What the Program Does Not Include

Our program is fully remote with no office visits or in-person physical exams. Ongoing labs are not bundled into the $199. We route patients to direct-pay lab companies where the relevant panel typically runs $50 to $80 out of pocket. Additional therapies carry separate pricing and are presented transparently before anything is added to a protocol.

Some patients exploring TRT also benefit from sermorelin to support the growth hormone axis alongside testosterone. For how those two systems interact, see Does Sermorelin Increase Testosterone?.

Why Insurance Almost Never Covers This

TRT prescribed for low testosterone is almost universally excluded from standard insurance coverage, even with confirmed labs. Insurers frequently reject claims on grounds that the condition is manageable without treatment, or because the medication is compounded rather than a branded pharmaceutical. Planning for out-of-pocket cost is the realistic approach.

$199 with real physician involvement is not a discounted version of TRT. It is what TRT should cost when the overhead is honest and the science is respected.

FAQ

How much does TRT cost per month without insurance? Most men’s health clinics charge $400–600 a month for a full TRT program including medication and physician oversight. At Precision Telemed, our program is $199 a month and includes compounded testosterone cypionate, anastrozole, and provider management. Compounded testosterone cypionate has not been reviewed by the FDA and is not the same as commercially available testosterone products.

What is included in Precision Telemed’s TRT program? The $199 monthly fee covers compounded testosterone cypionate, anastrozole, and physician oversight through our telehealth platform. Labs are not bundled but we guide patients to affordable direct-pay options.

Why does compounded testosterone cost less than a traditional clinic? The medication itself is not expensive to produce. What inflates pricing at most clinics is facility overhead, staffing, and an in-person business model — not the drug.

Do I need labs before starting? Our clinical providers require it. They follow Bhasin 2018 Endocrine Society diagnostic guidelines. A lab order is provided for patients who don’t have current results, and we route patients to direct-pay labs to keep that cost manageable.

Is online TRT as safe as visiting a clinic? When managed by a licensed physician monitoring labs and adjusting the protocol, the oversight is what matters — not the physical location of the provider. Our clinical team handles that through the platform.

References

1. Hackett G et al. Testosterone replacement therapy: practical aspects. Ther Adv Urol. 2015;7(4):198-209. PubMed
2. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient discontinued TRT at week three. He felt more fatigued than before he started, his mood was inconsistent, and he had some mild water retention. He told me it was not working. When I reviewed his labs and timeline, everything was proceeding exactly as expected. He was three weeks into a therapy that typically takes eight to twelve weeks to produce its full clinical effect.

That experience changed how I onboard every new TRT patient. I now spend significant time before the first injection explaining what the first month actually looks like, what side effects of testosterone injections are expected versus concerning, and why the first-month experience is not representative of what TRT does over time. The pharmacology of testosterone cypionate provides the explanation, and once patients understand it, the early weeks become much easier to tolerate.

The Pharmacokinetics of Testosterone Cypionate

Testosterone cypionate has a specific pharmacokinetic profile that directly predicts when patients feel effects and why the early weeks are variable. After a subcutaneous or intramuscular injection, peak serum testosterone levels are reached at approximately 24 to 48 hours. The half-life of testosterone cypionate is approximately 8 days, meaning the concentration drops by half roughly every eight days after that peak. In a standard once-weekly injection protocol, this creates a cycle: a peak on day one to two, a gradual decline through the week, and a trough just before the next injection.

The trough is clinically relevant for patient experience. Before steady-state levels have been established, typically after three to five injection cycles, there can be a noticeable difference between how patients feel at peak and how they feel at trough. This fluctuation often manifests as variability in energy, mood, and libido across the week. When I explain the pharmacokinetics upfront, patients understand why they feel better on day two than on day seven, and they are far less likely to interpret the trough as treatment failure.

As the protocol progresses and steady-state serum levels are achieved, the peak-to-trough variation becomes more predictable and patients adapt to the rhythm. Some patients benefit from transitioning to twice-weekly smaller injections to flatten this curve, which becomes a clinical conversation when relevant.

Why the First Four to Six Weeks Feel Unpredictable

When testosterone is introduced exogenously, the body undergoes a period of hormonal recalibration beyond the simple pharmacokinetic curve. The enzyme CYP19A1, commonly known as aromatase, converts testosterone to estradiol. Aromatase is expressed primarily in adipose tissue. As testosterone levels rise in the early weeks of therapy, estradiol production increases proportionally. For some patients, this estrogen rise outpaces the downstream adaptation of hormone receptors, producing temporary symptoms including water retention, mood variability, and reduced energy. This typically self-corrects within the first four to six weeks as estrogen stabilizes and receptor sensitivity adjusts.

What I see in patients during this window is sometimes discouragement — a patient hoping for more energy and better mood may feel transiently worse before feeling better. The patient who quit at week three would have felt the full benefit by week eight. Better upfront education on what that window looks like is the most effective intervention.

Hematocrit: The Biology, the Risk, and Why Labs Are Non-Negotiable

Testosterone stimulates the production of erythropoietin (EPO) in the kidneys, the hormone that drives red blood cell production in the bone marrow. As EPO rises, hematocrit increases. This is a normal physiological effect of elevated testosterone, not a pathological one.

The clinical concern arises when hematocrit rises substantially. In clinical research, intramuscular testosterone injections produce a mean hematocrit increase of approximately 4.0 percent. Clinical significance is typically assigned when levels exceed 52 to 54 percent. As hematocrit rises, blood viscosity increases, and with it the theoretical risk of cardiovascular events including deep vein thrombosis. This is why lab monitoring is a required part of the protocol, not optional.

At Precision Telemed, providers monitor hematocrit alongside total testosterone, free testosterone, and estradiol. If hematocrit rises to concerning levels, the management options are dose adjustment, increased injection frequency with smaller individual doses, or therapeutic phlebotomy.

Side Effects of Testosterone Injections: Estrogen Conversion and the Role of Anastrozole

The CYP19A1 aromatase enzyme, expressed primarily in adipose tissue, converts testosterone to estradiol. The rate of this conversion varies meaningfully between individuals, with higher adipose tissue mass generally correlating with greater aromatase activity. When estradiol rises too high during TRT, patients can experience nipple sensitivity or tenderness, water retention, emotional lability, and reduced libido — symptoms caused by excess estrogen, not excess testosterone. This is one of the most common sources of confusion among patients new to TRT.

Anastrozole, an aromatase inhibitor, reduces the rate of testosterone-to-estradiol conversion. The goal is not to suppress estrogen to zero. Estradiol serves important functions in men including maintaining bone density, supporting cardiovascular health, and contributing to libido. The clinical target is to keep estradiol within a physiologically appropriate range, determined through lab monitoring rather than symptoms alone.

Not every patient needs the same anastrozole dose. Low estrogen in men produces its own set of symptoms: joint pain, low libido, depressed mood, and fatigue that mirrors the symptoms of low testosterone itself. A provider who monitors estradiol and adjusts anastrozole based on individual response produces far better outcomes than a fixed-dose approach applied uniformly.

Testicular Atrophy, the HPT Axis, and Fertility

Exogenous testosterone suppresses the hypothalamic-pituitary-testicular (HPT) axis through negative feedback. When the hypothalamus detects adequate circulating testosterone, it reduces GnRH secretion. Lower GnRH means lower LH and FSH from the pituitary. Without LH stimulation, the Leydig cells in the testes dramatically reduce endogenous testosterone production. Without FSH, spermatogenesis is suppressed. Over time, the testes atrophy from disuse, and sperm production may fall significantly with prolonged therapy.

For patients not concerned about fertility, testicular atrophy is typically a manageable cosmetic change rather than a health risk. For patients interested in preserving fertility, this conversation needs to happen before therapy begins. Gonadorelin, a synthetic GnRH analogue, can be administered alongside TRT to maintain LH and FSH secretion and prevent full testicular function suppression. Clomiphene citrate offers an alternative mechanism. Patients who come to me with fertility concerns receive a different protocol structure than those who do not — and that discussion happens before the first injection.

Some patients dealing with overlapping low testosterone and low IGF-1 may benefit from sermorelin alongside TRT. For a full explanation of how the growth hormone and testosterone axes interact, see Does Sermorelin Increase Testosterone?.

Long-Term Outcomes: What the Research Shows

The long-term data on appropriately managed TRT is reassuring. Data published in the European Heart Journal found that patients receiving TRT who normalized their serum testosterone levels had a significantly lower risk of all-cause mortality, myocardial infarction, and stroke compared to patients whose testosterone levels did not normalize with therapy (Sharma et al., Eur Heart J 2015, PMID 26048144). The key phrase is “normalized” — the protective association was observed in patients whose testosterone was brought into a normal physiological range with monitoring and dose management, not supraphysiologic levels.

The thirty-day window that first-month patients experience is an adjustment phase. The cardiovascular and metabolic benefits described in the literature are cumulative and develop over months.

Injection Site Management

Testosterone cypionate is an oil-based formulation. Cold oil is more viscous and more uncomfortable to inject. Holding the vial in the hand or warming it briefly under warm water before drawing reduces injection resistance substantially. Rotating between multiple sites — the lateral quadriceps, ventrogluteal area, and deltoid — prevents tissue buildup and microfibrosis at any single location. Patients who inject consistently at the same site often develop soreness and firmness that is entirely preventable with rotation.

FAQ

Q: How long before TRT produces noticeable benefits? Energy and mood improvements often begin within two to four weeks. Libido improvements are typically more evident at weeks six to twelve. Full body composition changes generally require three to six months of consistent therapy. The first month is an adjustment and calibration period, not the full clinical experience.

Q: Is long-term TRT safe? Long-term TRT is considered safe for appropriately selected patients who are monitored regularly — ongoing monitoring of hematocrit, testosterone levels, estradiol, PSA (in men over 40), and general metabolic panels. Patients managed with appropriate lab follow-up and dose adjustment have a well-established safety profile in the clinical literature.

Q: Why is hematocrit monitored so closely? Testosterone stimulates EPO production in the kidneys, which increases red blood cell production and raises hematocrit. When hematocrit rises significantly, it increases blood viscosity and can elevate cardiovascular risk. Monitoring allows providers to detect and manage this before it becomes a clinical concern.

Q: What is anastrozole and why is it included? Anastrozole is an aromatase inhibitor that reduces the CYP19A1-mediated conversion of testosterone to estradiol. When estrogen rises too high during TRT, patients can experience water retention, mood changes, nipple sensitivity, and reduced libido. Including anastrozole in the protocol helps manage this proactively. Dosing is individualized based on labs and symptom response.

Q: Can fertility be preserved while on TRT? Yes, with additional medications. Gonadorelin and clomiphene citrate are two options that support continued pituitary and testicular signaling during testosterone therapy. Patients for whom fertility preservation is a priority should discuss this with their provider before starting therapy so the protocol can be structured accordingly from the beginning.

Q: What should patients do if they experience side effects in the first few weeks? Most early side effects — including injection site reactions, mild water retention, mood variability, and fatigue — are part of the adjustment period and resolve within four to six weeks. Precision Telemed providers are available through the platform for follow-up. Discontinuing therapy based on the first two to three weeks alone, without a provider consultation, forfeits the adaptation progress already underway.

References

1. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
2. Hackett G et al. Testosterone replacement therapy: practical aspects. Ther Adv Urol. 2015;7(4):198-209. PubMed
3. Sharma R et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-2715. PubMed
4. Snyder PJ et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Is Compounded Semaglutide the Same as Ozempic? The Honest Answer After Two Years of Running a GLP-1 Program

Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient who found our program last year shared that she had driven two hours each way to a weight loss clinic in another city, paid $1,200 out of pocket for a two-month supply of Ozempic, and then made the same drive again when her prescription ran out. She came to us after her third trip with a question our team hears constantly: is compounded semaglutide the same as Ozempic, and if so, why does ours cost less?

The short answer no. The longer answer is worth understanding, and my pharmaceutical background puts me in a position to explain it clearly — not as clinical guidance, but as someone who understands drug development, supply chains, and what actually drives price in this market.

What These Products Have in Common, and Where They Diverge

Ozempic and Wegovy are FDA-approved products whose active ingredient is semaglutide, a GLP-1 receptor agonist with a specific amino acid sequence and fatty acid side chain that gives it its long half-life of approximately seven days. Compounded semaglutide is formulated by a 503A pharmacy. It has not been reviewed or approved by the FDA, and its potency, purity, and clinical performance cannot be assumed to match the approved products.

That does not make them the same product. Compounded semaglutide has not been reviewed or approved by the FDA and is not the same finished drug product as Ozempic or Wegovy. Because it is not FDA-reviewed, the equivalence, potency, and purity assurances that apply to the approved products do not automatically apply to a compounded formulation. The delivery device, the formulation, the manufacturer, the price, and the supply chain all differ as well. Those are important distinctions, and I want to be direct about them.

For a cellular-level explanation of how semaglutide acts on the GLP-1 receptor, see How Semaglutide Works at a Cellular Level.

The Formulation Differences Are Real

Ozempic uses polysorbate 80 as a surfactant, along with a pH-buffered vehicle, disodium phosphate dihydrate, and sodium chloride. Compounded semaglutide typically uses bacteriostatic water or a comparable sterile vehicle as the diluent, with pH adjustment as appropriate. The excipients are different, the preparation is different, and the compounded product has not gone through the FDA’s review process for the finished drug product. Our clinical team discusses this with every patient before they start.

Why Brand Ozempic Costs So Much More

Ozempic’s U.S. list price of approximately $900 to $1,000 per month reflects patent exclusivity, decades of R&D investment, a global regulatory approval infrastructure, and a large commercial sales organization. That price is built on patent economics, not production cost.

Compounded semaglutide doesn’t carry any of that overhead. A 503A compounding pharmacy sources active pharmaceutical ingredient from an accredited supplier, prepares the medication in a licensed sterile compounding facility under USP Chapter 797 standards, and dispenses it under a valid prescription with documented clinical justification. The price reflects actual production cost rather than a patent return layered on top.

The international pricing comparison is instructive: Ozempic is available in Canada and the UK at a fraction of the U.S. price. Not because it is different there, but because most countries regulate pharmaceutical pricing and the U.S. largely does not.

The Regulatory Environment in 2026

From my pharmaceutical trade vantage point, the regulatory picture here has changed materially and patients deserve to understand it clearly. The FDA’s shortage-based pathway that permitted broad “essentially a copy” compounding of semaglutide ended when the shortage was declared resolved in February 2025. The operative framework now is the 503A patient-specific pathway, which permits compounding when a licensed prescriber documents a specific clinical reason the commercial product does not meet an individual patient’s need.

This is a narrower, more carefully documented practice than what existed during the shortage. Anyone offering compounded semaglutide without a clear clinical basis documented at the prescription level is not operating within that framework.

What I Think Every Patient Should Know Before Starting

One of the most consistent things I observe operationally is that patients don’t ask the right question early enough. They ask how much they’ll lose. They don’t ask what happens if they stop. GLP-1 therapy works while it is being taken, and appetite regulation tends to return toward baseline after stopping. Our clinical team frames this as a sustained management strategy rather than a finite course, so patients approach it with the right expectations from the start.

For patients weighing tirzepatide against semaglutide, see Tirzepatide vs Semaglutide, or review our compounded tirzepatide online program. For muscle preservation during weight loss, see The Protein and Resistance Training Protocol for GLP-1 Patients.

FAQ

Q: Is compounded semaglutide the same as Ozempic? No, they are not the same product. Compounded semaglutide is prepared by a 503A pharmacy and has not been reviewed or approved by the FDA, while Ozempic and Wegovy are FDA-approved products. The delivery device, formulation, manufacturer, regulatory status, price, and supply chain are all different. Because compounded semaglutide is not FDA-reviewed, its potency, purity, and clinical performance cannot be assumed to match the approved products. Our clinical team discusses this distinction with every patient.

Q: Is it still legal to prescribe compounded semaglutide? Under the 503A patient-specific framework, yes — when a licensed prescriber documents a specific clinical reason the commercial product does not meet that patient’s need. The shortage-based pathway that allowed broad compounding ended in April 2025.

Q: Why does Ozempic cost so much more? U.S. pharmaceutical pricing is largely unregulated at the product level. Ozempic’s price reflects patent exclusivity, R&D investment, and large commercial infrastructure. Semaglutide is available at substantially lower prices in most other countries. Compounded semaglutide reflects actual production cost without the patent economics.

Q: What happens to weight if someone stops GLP-1 therapy? Appetite regulation tends to return toward baseline after stopping, and many patients find weight returns without a maintenance plan in place. Our clinical team discusses this before anyone starts so expectations are grounded from the outset.

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

I have had patients come in wanting testosterone replacement therapy who, six months on sermorelin, had testosterone levels that no longer warranted it. That is not the outcome I expected when I first started considering sermorelin as a first step for borderline cases. But it happened enough, and consistently enough, that it changed how I sequence hormonal evaluation in men with overlapping symptoms.

The question of whether sermorelin increases testosterone is one I hear regularly. The connection between the growth hormone axis and the testosterone axis is real, measurable, and grounded in specific molecular biology. It is also widely misunderstood.

Does Sermorelin Increase Testosterone? What Sermorelin Does and Does Not Do for Testosterone

Sermorelin does not directly stimulate testosterone production. It acts on the pituitary’s somatotroph cells to increase growth hormone secretion through the GHRH receptor pathway, which in turn raises IGF-1. There is no direct sermorelin receptor on the Leydig cells of the testes where testosterone is synthesized. Claims to the contrary simplify the endocrinology to the point of inaccuracy.

What sermorelin does do is support several of the upstream conditions that allow the hypothalamic-pituitary-gonadal axis to function well. Understanding why requires a brief account of how the testosterone axis actually works and where it is vulnerable to disruption.

The HPG Axis and Where It Breaks Down

Testosterone production follows a precise signaling chain. Gonadotropin-releasing hormone, or GnRH, is released in a pulsatile pattern from the hypothalamus, typically every 90 to 120 minutes. Each GnRH pulse reaches the anterior pituitary and stimulates the release of luteinizing hormone and follicle-stimulating hormone. LH travels through the bloodstream to the Leydig cells in the testes, where it binds to LH receptors and triggers the steroidogenic cascade. The first and rate-limiting step involves the steroidogenic acute regulatory protein, or StAR, which transports cholesterol across the inner mitochondrial membrane, making it available for enzymatic conversion to testosterone.

This is the distinction between secondary and primary hypogonadism that guides clinical decisions. In primary hypogonadism, the testes themselves are damaged or dysfunctional — LH is high because the pituitary is trying harder in response to low testosterone. In secondary hypogonadism, the testes are capable of producing testosterone but the upstream LH signal is insufficient. This is where sermorelin’s indirect pathway becomes relevant, because several of the mechanisms that suppress the GnRH-LH-testosterone axis are the same mechanisms that also suppress growth hormone secretion.

How Sleep Deprivation Disrupts Both Axes Simultaneously

The most direct connection between the GH axis and the testosterone axis runs through sleep architecture. Testosterone secretion follows a strong nocturnal pattern, with the largest pulses occurring during slow-wave sleep in the early part of the night. Growth hormone also reaches its daily peak during slow-wave sleep. These two anabolic hormones share the same sleep-dependent window. When slow-wave sleep is compressed by sleep deprivation, fragmented sleep, or age-related sleep architecture changes, both decline together.

The mechanism involves cortisol. Sleep deprivation elevates evening cortisol, and cortisol directly suppresses GnRH release from the hypothalamus. With GnRH reduced, the pulsatile LH signal that the Leydig cells depend on weakens. Fewer and smaller LH pulses mean less StAR protein expression and less testosterone synthesis. Cortisol also suppresses GH secretion at the pituitary level, which is why the two hormones fall together during sleep deprivation and can, in the right patients, recover together.

Research published in Neuroendocrinology by Steiger and colleagues demonstrated that pulsatile GHRH administration increased slow-wave sleep from 14.0 to 20.2 percent of total sleep time — a 44 percent relative increase — alongside elevated nocturnal GH secretion. (PubMed) Restoring slow-wave sleep architecture through GHRH signaling creates conditions under which nocturnal GnRH pulsatility and LH release can also recover.

IGF-1’s Supporting Role in Gonadal Function

There is an additional mechanism that connects sermorelin’s effects to testosterone production, operating through IGF-1 rather than sleep. IGF-1 receptors are expressed on Leydig cells, and IGF-1 acts as a permissive factor for LH-stimulated steroidogenesis. In the presence of adequate IGF-1, Leydig cells are more responsive to LH. When IGF-1 is severely suppressed — as it is in patients with significant GH axis decline — LH stimulation alone is insufficient to generate a full testosterone response.

This permissive effect means that raising IGF-1 through sermorelin therapy can improve the efficiency of whatever LH signal is already present. A retrospective review by Sigalos and Pastuszak published in Sexual Medicine Reviews found that men on growth hormone secretagogue therapy saw IGF-1 rise from a mean of 159.5 ng/mL to 239.0 ng/mL over a mean of 134 days — a 50 percent increase with statistical significance. (PubMed) In patients where low IGF-1 was contributing to gonadal underperformance, that magnitude of IGF-1 recovery has meaningful implications for testosterone production.

When Sermorelin Is Enough and When TRT Is Necessary

For a man in his mid-40s with total testosterone in the 350 to 450 ng/dL range, symptoms of fatigue, poor recovery, reduced libido, and early body composition changes, I now look closely at the full lab picture before recommending TRT. LH and FSH are essential. If LH is low or low-normal alongside low testosterone, the problem is upstream — secondary hypogonadism — and sermorelin is a rational first intervention. If LH is elevated, the testes are already being maximally stimulated and failing to respond — primary hypogonadism — and sermorelin will not help.

IGF-1 on baseline labs is equally important. When IGF-1 is low alongside borderline testosterone, I strongly consider sermorelin first. The two deficits often share the same root cause in disrupted nocturnal hormonal secretion, and addressing the GH axis frequently moves both IGF-1 and testosterone in the right direction over three to six months. Patients with testosterone below 300 ng/dL, confirmed primary hypogonadism, or significant symptomatic burden are generally not candidates to wait.

For a complete overview of what TRT involves and how our program is structured, see the TRT information page here. For an explanation of what to expect in the first months of TRT, see our blogs here.

When Combining Sermorelin and TRT Makes Clinical Sense

The combination of sermorelin and testosterone replacement is one I use regularly for patients already on TRT but experiencing a suboptimal response. TRT replaces testosterone but does not address the growth hormone axis. Many men on TRT still have low IGF-1, poor recovery, and persistent body composition challenges because GH decline with age is a separate biological process from testosterone deficiency.

Adding sermorelin to an established TRT protocol frequently produces results that neither therapy achieves alone. The Sigalos and Pastuszak data showing a 50 percent IGF-1 rise is relevant here — men on TRT who achieve meaningful IGF-1 elevation on top of adequate testosterone levels have both axes supported simultaneously. Lean mass response is more robust. Recovery improves further. Cognitive clarity and energy often reach a level that TRT alone did not produce. The two therapies operate on different receptor systems through different downstream pathways and do not conflict — they complement each other.

Precision Telemed’s Approach to Sequencing

At Precision Telemed, sermorelin is priced at $199.99 per month and TRT at $199 per month, both available in all 50 states through 503A compounding pharmacies. The async model supports staged decision-making well — patients can start on sermorelin, recheck labs at six to eight weeks, and make data-driven decisions about whether to add TRT at that point without waiting months for an in-person follow-up.

For a deep clinical look at how sermorelin dosing and titration work and what labs to monitor, see How I Dose Sermorelin for Body Composition.

FAQ

Q: Does sermorelin directly increase testosterone levels? No. Sermorelin does not act directly on testosterone production pathways. Its potential to support testosterone levels is indirect — through improved slow-wave sleep architecture that allows nocturnal GnRH and LH pulsatility to recover, reduced cortisol-mediated suppression of the HPG axis, and IGF-1-mediated enhancement of Leydig cell responsiveness to LH stimulation.

Q: How long does sermorelin take to affect testosterone levels? If sermorelin is going to affect testosterone indirectly, it typically does so over a three to six month window — consistent with the time needed for sleep architecture improvement, IGF-1 elevation, and cortisol normalization to translate into HPG axis recovery.

Q: Can sermorelin replace testosterone therapy? In some cases involving borderline low testosterone, secondary hypogonadism, and clear upstream contributing factors such as low IGF-1 and disrupted sleep, sermorelin may produce sufficient improvement to avoid TRT. In primary hypogonadism or significantly low testosterone with elevated LH, it cannot substitute for replacement therapy.

Q: What labs should be checked before deciding between sermorelin and TRT? At minimum: total testosterone, free testosterone, LH, FSH, IGF-1, and cortisol. LH and FSH distinguish primary from secondary hypogonadism. IGF-1 indicates whether the GH axis is a meaningful contributing factor. This lab picture is essential before making a clinical recommendation.

Q: Is it safe to take both sermorelin and testosterone at the same time? Yes. Many providers use this combination intentionally. Sermorelin addresses the GH axis via GHRH receptor signaling and IGF-1 elevation. TRT addresses the HPG axis by replacing circulating testosterone. They operate through different receptor systems and do not conflict.

Q: Will the body stop producing testosterone if TRT is started? Yes, to varying degrees. Exogenous testosterone suppresses GnRH pulsatility and LH secretion, which reduces endogenous Leydig cell stimulation. Patients for whom fertility preservation is a priority should discuss this with their provider before starting therapy so the protocol can be structured accordingly.

Q: Why would testosterone improve on sermorelin if sermorelin does not target testosterone directly? Because testosterone production depends on a functioning hormonal environment, not just on adequate LH stimulation alone. Sleep deprivation, elevated cortisol, and low IGF-1 all impair the system. Sermorelin addresses several of those upstream factors, and in patients where those factors are the primary driver of the decline, the testosterone axis recovers as a consequence of the broader hormonal environment improving.

References

1. Steiger A et al. Nocturnal sleep EEG and secretion of GH and cortisol after administration of GHRH. Neuroendocrinology. 1992;56(4):566-573. PubMed
2. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed

To speak with one of our licensed providers about whether this is right for you, visit www.precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

The question comes up almost every time someone starts looking into our program. They have done their research, read something online, maybe heard something skeptical from a family member. Before anything else, they want to know: is compounded semaglutide safe, or is this something sketchy off the internet?

I never rush past that question. It deserves a direct answer. And the fact that I own a pharmacy that compounds medication means I can give one that most telehealth providers simply cannot.

The skepticism is warranted — and more warranted now than two years ago. The FDA has been active in this space. More than 55 warning letters went out to compounders and telehealth firms in 2025 alone. Major platforms have exited the compounded GLP-1 market entirely. There is a legitimate gray market for GLP-1 compounds operating completely outside any regulatory framework. What we do at Precision Telemed is nothing like that, and the difference is specific and verifiable.

What a 503A Compounding Pharmacy Actually Is

A 503A pharmacy is a licensed compounding pharmacy operating under state pharmacy board oversight and following the sterile compounding standards set by the United States Pharmacopeia, specifically USP Chapter 797. Congress created the 503A framework to allow licensed pharmacists to prepare customized medications for individual patients when commercially available products do not meet a specific clinical need. State boards have inspection authority. Pharmacists must meet licensure requirements. The facility must pass periodic inspections.

USP Chapter 797 establishes enforceable standards for sterile compounding — cleanroom design, environmental monitoring, personnel training, equipment qualification, sterility testing, beyond-use dating, and microbial contamination controls. These are not guidelines. They are the baseline a licensed facility must meet or face regulatory action.

Compounded semaglutide prepared under this framework has not been reviewed or approved by the FDA and is not the same as commercially available Ozempic or Wegovy. That distinction matters — it is not something to gloss over, and I don’t.

The Regulatory Landscape in 2025–2026: What Changed and What Didn’t

My pharmaceutical trade background means I follow regulatory developments in this space closely — and there has been significant change that anyone evaluating compounded GLP-1s deserves to understand.

The FDA declared the semaglutide shortage resolved in February 2025. The broad shortage-based pathway that had allowed 503A pharmacies to compound “essentially a copy” semaglutide at scale closed in April 2025. What did not close is the core 503A framework for patient-specific compounding, which permits a licensed prescriber to document that a compounded formulation produces a clinically significant difference for an individual patient — a dose strength not available in the commercial pen, for example. That is a narrower, more carefully documented practice than what operated during the shortage, and it is how legitimate 503A operations are functioning in 2026.

Why I Built the Pharmacy Myself

I evaluated third-party compounding partners early in building this business. I came away unimpressed more than once. My pharmaceutical background gave me a clear picture of what a quality system looks like and what it does not. I was not willing to build a telehealth practice on a supply chain I did not fully control — so I built a relationship with a 503A pharmacy that meets that standard, with ongoing compliance oversight baked into the model.

That was the harder path. It was also the only acceptable one from where I stood.

What Certificate of Analysis Testing Actually Verifies

Every batch of active pharmaceutical ingredient we use undergoes COA testing from an independent, accredited laboratory. A properly conducted COA for a pharmaceutical-grade compound includes identity testing by HPLC (confirming it is actually semaglutide, not a structural analog), potency testing (confirming concentration within acceptable tolerance), sterility testing (absence of viable microbial organisms), and endotoxin testing (bacterial endotoxin levels that could cause serious reactions if injected).

That is objective, third-party documentation that the medication is what it claims to be. I can show the COA for the batch any given patient’s medication was made from. That level of traceability does not exist when someone orders peptides from an unregulated website under a research-use-only disclaimer. The distinction is specific and large.

The Clinical Safety Record of the Active Molecule

Separate from the compounding question is the molecule itself. The STEP 2 trial enrolled adults with overweight or obesity and type 2 diabetes and demonstrated meaningful weight reduction with a well-characterized side effect profile (Davies et al., Lancet 2021, PMID 33667417). GI effects — nausea most prominently — were the dominant adverse events, dose-dependent, and improved over time for most patients.

Per the FDA, the active molecule in compounded semaglutide cannot be compared to the the same molecule studied in those trials. What changes with compounding is the inactive ingredients, the delivery device, and the price. What does not change is that compounded semaglutide has not been FDA-reviewed as a finished drug product. That is a meaningful difference from FDA-approved options, and our clinical team discusses it with every patient.

For more on the molecule itself, see How Semaglutide Works at a Cellular Level. For a direct comparison with brand-name Ozempic, see Is Compounded Semaglutide the Same as Ozempic?.

What to Ask Any Telehealth Provider

Anyone evaluating a telehealth provider offering compounded semaglutide should be able to get answers to these questions: Is the pharmacy 503A-licensed? Can they provide COA documentation? Where does their API come from? What sterile compounding standards are they following? What is the documented clinical basis for the compounded prescription for that specific patient?

These are not difficult questions for a legitimate operation. They are only difficult if the answers are unflattering.

FAQ

Q: Is compounded semaglutide FDA-approved? No. Compounded semaglutide is not FDA-approved as a finished drug product. It is prepared under the 503A compounding pharmacy framework, which is regulated through state pharmacy board oversight and USP Chapter 797 standards. It is not the same as commercially available FDA-approved semaglutide products.

Q: How is compounded semaglutide different from buying peptides online? They are completely different in regulatory status. Compounded semaglutide from a licensed 503A pharmacy requires a valid prescription, undergoes COA testing, and is subject to state board inspections. Peptides sold online without a prescription carry a research-use-only disclaimer and operate entirely outside pharmaceutical regulatory frameworks.

Q: What does a certificate of analysis tell me about my medication? A COA from an independent accredited laboratory confirms identity by HPLC, potency within acceptable tolerances, sterility, and endotoxin levels — objective third-party documentation of what the medication is and what it contains.

Q: Is it still legal to prescribe compounded semaglutide in 2026? Under the 503A patient-specific framework, yes — when a licensed prescriber documents a specific clinical reason the commercial product does not meet the patient’s individual need. The broad shortage-based pathway ended in April 2025. Patients should ask any provider to explain the clinical basis for a specific compounded prescription.

Q: How do I verify a telehealth provider is using a legitimate pharmacy? The pharmacy name, 503A license status, and COA documentation are all things a legitimate provider should be able to supply on request. Pharmacy license status can be verified through the relevant state pharmacy board website in a matter of minutes.

References

1. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of the licensed providers for personalized clinical guidance.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient came to see me about a year ago carrying a printout from a news article about semaglutide and heart disease. He was 58 years old, had a history of a myocardial infarction four years prior, and his BMI was 31. He had been told by two previous physicians that GLP-1 therapy was for diabetics and for people with severe obesity. He sat across from me and asked if that was still true.

I told him it was not. The SELECT trial changed how I think about semaglutide heart health benefits in ways that go beyond expanding a patient population. It forced a reckoning with a question that had been sitting in the background of cardiovascular medicine for years: whether the cardiovascular benefit we were seeing in GLP-1 trials was a consequence of lowering blood sugar, or whether it reflected something more fundamental about how these drugs interact with the cardiovascular system.

What the SELECT Trial Was and Why It Matters

The SELECT trial was published in the New England Journal of Medicine in November 2023. It enrolled 17,604 adults across 41 countries. The participants were 45 years of age or older, had a BMI of 27 or above, had established cardiovascular disease, and had no history of diabetes. (PubMed) This last criterion is what separated SELECT from everything that came before it.

Every patient in this trial was already receiving aggressive cardiovascular risk reduction — statins, antihypertensives, antiplatelet agents. Semaglutide was tested as an additional intervention against that standard-of-care background. Participants were randomized to receive either once-weekly subcutaneous semaglutide at 2.4 mg or placebo and followed for a mean of 33 months.

The Primary Endpoint: What MACE Means and Why It Is the Right Measure

The primary endpoint of SELECT was MACE: major adverse cardiovascular events. MACE is the gold standard composite endpoint in cardiovascular outcomes research because it captures the three events that define the prognostic reality of heart disease: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. These are not surrogate markers or intermediate biochanges. They are the outcomes that kill and disable patients with established cardiovascular disease.

The SELECT trial found a 20 percent relative risk reduction in MACE in the semaglutide group compared to placebo. The hazard ratio was 0.80, with a 95 percent confidence interval of 0.72 to 0.90, and a p-value below 0.001. Among patients already on widespread statin therapy and aggressive cardiovascular risk management, semaglutide still reduced the primary endpoint by 20 percent.

If a patient has a 10-year MACE risk of 20 percent, a 20 percent relative reduction brings that risk to approximately 16 percent. Four fewer events per 100 patients over that time horizon. In a population as large and high-risk as the one enrolled in SELECT, that is an enormous number of prevented deaths, strokes, and heart attacks.

Why This Is Different From Every Prior GLP-1 Trial

Before SELECT, the cardiovascular evidence for GLP-1 receptor agonists came from trials in diabetic populations. The LEADER trial with liraglutide showed a 13 percent reduction in MACE in patients with type 2 diabetes. (PubMed) The SUSTAIN-6 trial with semaglutide showed a 26 percent reduction in MACE in patients with type 2 diabetes. (PubMed) Both were compelling results. But both left open a critical interpretive question: was the cardiovascular protection a consequence of improved glycemic control, or was it something the drug was doing independently of its glucose-lowering effects?

SELECT removed that question from the table. There was no diabetes in this population. No glycemic mechanism could explain the outcome. Something else was driving the benefit.

The Mechanisms Behind a Non-Glycemic Cardiovascular Benefit

GLP-1 receptors are expressed in cardiac tissue, not only in the pancreas and gut. At the cardiac level, GLP-1 receptor activation reduces local inflammation, improves cardiac energetics by shifting myocardial substrate utilization toward more oxygen-efficient pathways, and has been shown in preclinical models to reduce ischemia-reperfusion injury. These are direct effects on the heart muscle, operating independently of weight loss or glucose changes.

Weight loss itself carries cardiovascular benefits that are separate from metabolic improvements. Reducing body weight decreases cardiac preload by reducing circulating volume and venous return to the heart, and decreases cardiac afterload by reducing the systemic vascular resistance that an enlarged body mass imposes. Over months and years, these hemodynamic improvements reduce the mechanical burden on a heart that has already experienced ischemic damage.

There is also an anti-inflammatory mechanism. Visceral adiposity is metabolically active in ways that promote systemic inflammation, and inflammation is a direct driver of atherosclerotic plaque development and destabilization. As visceral fat decreases with semaglutide treatment, circulating inflammatory cytokines fall, and the inflammatory microenvironment within existing atherosclerotic plaques may change in ways that reduce the likelihood of acute rupture and thrombosis.

Who This Applies To and How I Think About Eligibility

SELECT enrolled patients who were overweight or obese, had established cardiovascular disease, and were not diabetic. That describes a very large number of people who have had a heart attack, a stent placement, a stroke, or a diagnosis of peripheral arterial disease or coronary atherosclerosis, who carry excess weight, and who have been told that semaglutide was not indicated for them.

The reality after SELECT is that these patients are exactly who this therapy was tested in and found to benefit. For a patient with established cardiovascular disease and a BMI of 27 or above, semaglutide now belongs in the risk reduction conversation alongside statins and antihypertensives. The framing of GLP-1 as a diabetes drug does not survive contact with a 17,604-person randomized controlled trial showing a 20 percent reduction in cardiovascular death, myocardial infarction, and stroke in a non-diabetic population.

My eligibility thinking has shifted considerably. I now approach patients with prior cardiovascular events and excess weight as candidates for a conversation about semaglutide on the same terms I would approach a conversation about adding a second antihypertensive or a PCSK9 inhibitor.

A Note on Access and the Current Regulatory Environment

For patients who are appropriate candidates for semaglutide-based cardiovascular risk reduction, the access question matters. Branded semaglutide (Wegovy at 2.4 mg, the dose studied in SELECT) can exceed $1,000 per month without insurance coverage, and coverage for weight management indications remains inconsistent across plans.

The regulatory landscape for compounded semaglutide has changed significantly since 2024. The FDA’s shortage-based pathway that allowed broad compounding of semaglutide ended when the shortage was declared resolved in February 2025. What remains available through the 503A framework is patient-specific compounding when a licensed prescriber documents a clinical need the commercial product cannot address — a specific dose strength, for example.

Patients evaluating their options should understand both what the branded product offers and what the current compounding framework permits. For a full explanation of the 503A framework and what responsible compounding involves, see What I Tell Every Patient Who Asks Whether Compounded Semaglutide Is Real Medication. For a direct comparison of compounded semaglutide and branded Ozempic/Wegovy, see Is Compounded Semaglutide the Same as Ozempic?.

Precision Telemed’s Semaglutide Program

At Precision Telemed, compounded semaglutide is available at $149 per month, fulfilled through 503A compounding pharmacies, and managed entirely through async telehealth. Patients in all 50 states can access a clinical evaluation without an in-person visit.

For patients who have a cardiovascular history and have been turned away from GLP-1 therapy because a previous provider was not current with the SELECT data, I would encourage a direct conversation with a licensed provider about their specific history and labs. The indication picture changed in November 2023. The old answer is no longer the right answer for a lot of people.

FAQ

What was the SELECT trial? The SELECT trial was a randomized, placebo-controlled clinical trial published in the New England Journal of Medicine in 2023. It enrolled 17,604 non-diabetic adults with established cardiovascular disease and a BMI of 27 or above, testing once-weekly semaglutide 2.4 mg against placebo over a mean of 33 months, with all participants on background standard cardiovascular care.

What did the SELECT trial find? Semaglutide reduced the risk of MACE — the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by 20 percent compared to placebo. The hazard ratio was 0.80 (95% CI 0.72–0.90, p less than 0.001), in a population with no history of diabetes.

Does semaglutide only benefit people with diabetes? No. The SELECT trial was specifically designed to test non-diabetic patients. The cardiovascular benefit was observed in the complete absence of a glycemic mechanism, which indicates the benefit comes from the drug’s direct cardiovascular effects, anti-inflammatory properties, and hemodynamic improvements from weight loss.

What does MACE mean and why does it matter? MACE stands for major adverse cardiovascular events: the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. It is the standard primary endpoint in cardiovascular outcomes trials because it captures the most serious and life-altering events that heart disease produces. A 20 percent relative reduction in MACE reflects prevention of actual deaths and disabling events.

What are the non-glycemic mechanisms behind semaglutide’s cardiovascular benefit? Three primary mechanisms appear to operate. First, GLP-1 receptors in cardiac tissue mediate direct anti-inflammatory and cardioprotective effects. Second, sustained weight loss reduces cardiac preload and afterload, lowering the mechanical burden on the heart. Third, reductions in visceral adiposity lower systemic inflammatory cytokine levels, which may stabilize atherosclerotic plaques.

Who should consider semaglutide for cardiovascular risk reduction? Based on the SELECT trial, patients with established cardiovascular disease and a BMI of 27 or above represent the population in which cardiovascular benefit has been directly demonstrated. Whether semaglutide is appropriate for a specific individual depends on their full medical history, current medications, and a clinical evaluation by a licensed provider.

Is compounded semaglutide as effective as branded semaglutide? It is impossible to make this distinction since compounded semaglutide has never been studied. Compounded semaglutide uses the same active pharmaceutical ingredient as branded formulations when prepared by a licensed 503A compounding pharmacy under appropriate quality controls. Patients should discuss the current regulatory basis for any compounded semaglutide prescription with their provider, particularly given the changes in the compounding landscape since early 2025.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

References

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed
3. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult your healthcare provider.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient came to me last year after spending three years on a strict calorie-restriction diet. She had lost weight twice and regained it both times. She was convinced her body was broken. When I explained how compounded semaglutide works — and why her previous experience was not a failure of willpower but a failure of biology — she got quiet for a moment. Then she said, “Why did no one ever explain it that way?”

That exchange captures what most patients need before starting any medication: a real explanation of the mechanism, not a sales pitch. The science here is genuinely illuminating, and once patients understand it, the clinical decisions we make together start to make a lot more sense.

Where GLP-1 Comes From and What It Does

GLP-1, or glucagon-like peptide-1, is a hormone produced by enteroendocrine L-cells located in the lining of the small intestine and colon. These cells detect the arrival of nutrients in the gut and release GLP-1 within minutes of a meal. What happens next is a coordinated cascade that involves the pancreas, the brain, and the gastrointestinal tract simultaneously.

One of the most striking findings in metabolic research is how central GLP-1 is to normal insulin release. In healthy subjects, GLP-1 accounts for roughly 50 to 70 percent of the postprandial insulin response — a phenomenon called the incretin effect. After eating, it is not simply high blood sugar that tells the pancreas to release insulin. The gut signals ahead, via GLP-1 and related hormones, before glucose even reaches peak levels in the bloodstream. This anticipatory signaling is elegant and efficient. In many patients with obesity or metabolic dysfunction, this system is blunted, and semaglutide restores the volume of that signal.

A Molecule That Mimics and Amplifies the Natural Signal

Semaglutide is a synthetic GLP-1 analogue, meaning it is a molecule engineered to bind GLP-1 receptors with high affinity and resist the rapid enzymatic breakdown that limits the native hormone’s activity. Natural GLP-1 has a plasma half-life of less than two minutes because an enzyme called DPP-4 degrades it almost immediately. Semaglutide’s molecular structure includes modifications that make it resistant to DPP-4 and allow it to bind to albumin in the bloodstream, extending its half-life to approximately one week. This is why once-weekly dosing is pharmacologically sound.

The pharmacological durability of semaglutide is what transforms a brief gut signal into a sustained therapeutic effect. The molecule is doing something the body’s own GLP-1 cannot: staying active long enough to continuously engage the receptor network.

The Receptor Network: Where in the Body GLP-1 Acts

GLP-1 receptors are not confined to the pancreas. They are distributed across multiple organ systems, and understanding where they are explains most of semaglutide’s clinical effects.

In the gut, GLP-1 receptors are expressed on enteric neurons and smooth muscle, where they modulate motility and gastric emptying. In the peripheral nervous system, receptors are found on vagal afferent neurons in the nodose ganglion, which transmit gut-to-brain signals along the vagus nerve. This pathway carries real-time satiety information from the gastrointestinal tract directly to the brainstem nucleus tractus solitarius, where it is integrated with metabolic signals from other sources. From there, signals ascend to the hypothalamic arcuate nucleus, a region that acts as a master regulator of energy balance and hunger.

The result is what patients describe as “the food noise going quiet.” This is not suppression of hunger through effort. It is a measurable change in the neuroendocrine signals that generate the drive to eat.

How Gastric Emptying Creates Prolonged Satiety

The second major mechanism behind semaglutide’s weight effects is its action on the stomach. Semaglutide increases pyloric tone and reduces antral motility, resulting in a substantial slowing of gastric emptying: food remains in the stomach significantly longer than it would without the drug.

When the stomach empties more slowly, the physical stretch of the gastric wall that signals fullness is maintained for longer. Nutrients enter the small intestine at a slower rate, sustaining the postprandial satiety hormone release that would otherwise peak and drop rapidly. Patients feel full after smaller meals and remain satisfied longer between meals.

This gastric slowing is also the primary source of the nausea that patients experience during early titration — something our practice covers in detail at The Titration Protocol We Changed After Hearing the Same Complaint From Hundreds of Patients.

Blood Sugar Regulation and Insulin Sensitivity

Semaglutide acts directly on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner. This means insulin release occurs in response to elevated blood sugar, not continuously — which substantially reduces the risk of hypoglycemia. At the same time, semaglutide suppresses glucagon, the counter-regulatory hormone that raises blood glucose between meals, which stabilizes blood sugar levels throughout the day.

Patients without diabetes frequently ask why they feel less fatigued in the afternoon after starting semaglutide. Part of the answer is weight loss itself. But a significant part is the more stable blood glucose profile the drug produces — the energy crashes associated with reactive hypoglycemia, post-meal glucose spikes, and the hormonal noise of insulin resistance are all reduced.

What the STEP Trials Measured and Why the Numbers Matter

The clinical evidence behind semaglutide is among the strongest in the history of obesity pharmacotherapy. STEP 1, the landmark trial in adults with overweight or obesity without type 2 diabetes, showed a mean body weight reduction of 14.9 percent in the semaglutide group versus 2.4 percent in the placebo group at 68 weeks. Equally important: 86.4 percent of participants in the semaglutide group achieved at least 5 percent weight loss, a threshold widely used as a benchmark for clinically meaningful benefit on metabolic risk factors. In STEP 5, mean weight loss was 15.2 percent at 104 weeks, demonstrating durable effects over two years of continued treatment. Wilding JPH et al. N Engl J Med. 2021

Before these trials, outcomes of this magnitude were associated primarily with bariatric surgery. The mechanism is the same reason: both interventions correct underlying hormonal dysregulation rather than simply asking the patient to exert more effort against a biological system working against them. That patient who called herself “broken” was not broken. Her body was responding predictably to years of dysregulated incretin signaling and appetite hormones.

What Compounded Means and Why It Matters

Patients regularly ask whether compounded semaglutide works differently from the brand-name version. The active pharmaceutical ingredient is the same molecule. The mechanism of action is identical because the molecule is identical. Compounding refers to the process by which a 503A compounding pharmacy formulates the medication — typically in a vial for subcutaneous injection — using the same active ingredient. Importantly, compounded semaglutide has not been reviewed or approved by the FDA as a finished drug product and is not the same as commercially available Ozempic or Wegovy. Our clinical team discusses this distinction with every patient before starting.

The regulatory landscape for compounded semaglutide has evolved since 2024. The shortage-based pathway that allowed broad compounding ended when the FDA declared the shortage resolved in early 2025. What remains available is 503A patient-specific compounding when a licensed prescriber documents a clinical need the commercial product cannot address. For a full explanation, see What I Tell Every Patient Who Asks Whether Compounded Semaglutide Is Real Medication. For a direct comparison with branded Ozempic, see Is Compounded Semaglutide the Same as Ozempic?.

At Precision Telemed, compounded semaglutide is prepared through licensed 503A compounding pharmacies and dispensed through an async telehealth workflow, available in all 50 states.

Who Is a Candidate

The patients who respond best to semaglutide are those who have a meaningful history of weight cycling, difficulty maintaining weight loss through dietary changes alone, or who carry metabolic risk factors such as elevated fasting blood glucose, insulin resistance, or a family history of type 2 diabetes.

Patients who want to understand how semaglutide compares to tirzepatide can read Tirzepatide vs Semaglutide: What I Actually Tell Patients. For guidance on protecting lean muscle mass during weight loss on either medication, see The Protein and Resistance Training Protocol for GLP-1 Patients. And for patients with a cardiovascular history, the SELECT trial changed the evidence base significantly — see What the SELECT Trial Actually Means for Patients Who Are Not Diabetic.

Patients who are pregnant, who have a personal or family history of medullary thyroid carcinoma or MEN2, or who are currently taking certain other medications may not be appropriate candidates. A licensed provider reviews each patient’s history before any medication is started.

FAQ

Q: How quickly does semaglutide start working? Most patients in our practice notice appetite changes within the first two weeks. Weight changes typically become measurable by weeks four to six, with the most significant losses occurring over the first six to twelve months of consistent use.

Q: Is compounded semaglutide the same as brand-name semaglutide? The active pharmaceutical ingredient is the same molecule. The mechanism of action and expected clinical effects are identical. However, compounded semaglutide has not been reviewed or approved by the FDA and is not the same finished drug product as Ozempic or Wegovy. Our clinical team discusses this with every patient.

Q: What are the most common side effects? The most commonly reported side effects are gastrointestinal, including nausea, loose stools, and reduced appetite. These typically occur at dose initiation or escalation and improve over time for most patients. Slow titration significantly reduces their severity.

Q: Can patients stop semaglutide once they reach goal weight? This is a decision made with the treating provider. Clinical data shows that most patients regain approximately two-thirds of their lost weight within one year of stopping semaglutide. Some patients transition to a maintenance dose rather than stopping entirely.

Q: How is Precision Telemed’s semaglutide program structured? The program is fully asynchronous, available in all 50 states, and priced at $149 per month. A licensed provider reviews each patient’s intake and medical history. Medication is fulfilled through a licensed 503A compounding pharmacy. Follow-up care is available through the platform on an ongoing basis.

Q: Does semaglutide work without diet changes? Semaglutide produces weight loss even without formal dietary intervention, as demonstrated in the STEP trials. In practice, patients who make supportive nutritional changes alongside the medication tend to have better outcomes and preserve more lean mass during the weight loss period.

References

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PubMed
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. PubMed
4. Nauck MA et al. Incretin effects in healthy subjects and patients with type 2 diabetes. Diabetes. 2016;65(6):1490-1495. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.